Table 1.
Parameter | Population (n = 96) |
---|---|
Age | |
M ± SD | 69.65 ± 14.33 |
median (IQR 25–75) | 66.00 (57.00–88.00) |
Female Sex (%) | 28.9 |
BMI | |
M ± SD | 27.98 ± 5.00 |
median (IQR) | 27.68 (23.89–31.25) |
Smoking habit (%) | |
Never smokers | 36.1 |
Ex-smokers | 42.3 |
Current smokers | 3.1 |
CCI | |
M ± SD | 4.25 ± 2.66 |
median (IQR) | 4.00 (2.00–6.00) |
Asthma (%) | 17.5 |
COPD (%) | 17.5 |
Hypertension (%) | 70.1 |
Renal Failure (%) | 44.3 |
Congestive heart failure (%) | 22.7 |
Chronic ischemic heart failure (%) | 27.8 |
Neurological comorbidities (%) | 17.6 |
Number of peripheral lymphocyte cells | |
M ± SD | 928.39 ± 637.35 |
median (IQR) | 783.24 (629.18–1039.88) |
LDH | |
M ± SD | 332.20 ± 113.31 |
median (IQR) | 342.00 (245.00–396.00) |
CRP | |
M ± SD | 116.74 ± 79.99 |
median (IQR) | 106.00 (69.30–167.00) |
D-dimer | |
M ± SD | 2448.33 ± 3811.22 |
median (IQR) | 947.00 (581.00–2280.00) |
PaO2/FiO2 ratio at admission | |
M ± SD | 209.58 ± 94.00 |
median (IQR) | 198.00 (123.00–273.00) |
Respiratory support at admission (%) | |
Low flow oxygen | 9.3 |
HNFC | 3.1 |
CPAP | 38.1 |
BPAP | 36.1 |
IMV through tracheostomy | 7.2 |
Treatment | |
enoxaparin (%) | 81% |
azithromycin (%) | 80% |
lopinavir/ritonavir (%) | 38% |
hydroxychloroquine (%) | 74% |
tocilizumab (%) | 6% |
corticosteroids (%) | 25% |
Total Days of Hospitalization in RICU | |
M ± SD | 10.68 ± 8.94 |
median (IQR) | 10,00 (4,00–19.00) |
Exitus (%) | 46.4 |
M, mean; SD, standard deviation; IQR, interquartile range; BMI, body mass index; CCI, Charlson comorbidity index; COPD, Chronic obstructive pulmonary disease; LDH, Lactate dehydrogenase; CRP, C-reactive protein; PaO2/FiO2 ratio, arterial oxygen partial pressure to fractional inspired oxygen; HFNC, high-flow nasal cannula; CPAP, continuous positive airway pressure; BPAP, bilevel positive airway pressure; IMV, invasive mechanical ventilation; RICU, Respiratory Intermediate Care Units.